How LaViolette was paid
$7.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Paul A. LaVioletteChief Executive Officer and Co-Chairman | $708,523 | — | $6,717,960 | $1,416 | $7,427,899 |
| Jon SkinnerChief Financial Officer | $366,667 | $56,000 | $2,419,035 | $1,298 | $2,843,000 |
| Darrin R. UeckerChief Technology Officer and Director | $540,312 | $328,161 | — | $1,416 | $869,889 |
| Kevin P. DanahyFormer Chief Commercial Officer | $525,000 | $328,161 | — | $1,416 | $854,577 |
| Burke T. BarrettFormer Chief Executive Officer and Former Director | — | — | — | — | — |
| Mitchell E. LevinsonFormer Chief Strategy Officer and Former Director | — | — | — | — | — |
What changed and why
- $7.4M$7,427,899: CEO total compensation included a $6,717,960 option award.
- $16.2M$16,239,000: Maximum potential value of the CEO’s option award at grant.
- 70%70%: CEO annual target bonus as a percentage of annual base salary.
- $725K$725,000: CEO’s current annual base salary under his employment agreement.
- $2.8M$2,843,000: CFO total compensation included a $2,419,035 option award and $56,000 bonus.
- 2025: CEO and CFO received market-based and performance-based option awards.
Other Pulse Biosciences proxy statements
- 2025 proxy statement
Burke T. Barrett paid $8.4M.
Filed Oct 28, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.